Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAIR: Stop and Restart Acalabrutinib in Frail Patients With Untreated CLL
NCT04963946Phase 2Active, not recruiting
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Oct 2021
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of acalabrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by French Innovative Leukemia Organisation. Primary endpoint: Progression-Free Survival at 12 months. Started Oct 2021; status: active, not recruiting.
02
Drugs
acalabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04963946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04963946.